Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia
Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia
复制标题
DOI：
10.1159/000342772
复制
发表时间：
2013-01-01
影响因子：
2.4
通讯作者：
Lee, Jong Wook
中科院分区：
文献类型：
--
作者：
Lee, Sung-Eun;Yahng, Seung-Ah;Lee, Jong Wook
由于定期输注浓缩红细胞导致的铁过载可导致多器官损伤。铁螯合治疗（ICT）是重要的再生障碍性贫血（AA）患者谁需要输血作为支持管理。随着口服铁螯合剂地拉罗司的引入，ICT变得更加广泛和可行。我们研究了4例成人AA患者，他们有输血诱导的铁过载，并在口服地拉罗司ICT后显示血液学改善。地拉罗司治疗后，血红蛋白升高，血清铁蛋白水平降低，患者随后变得不依赖输血。我们的经验提高了信息和通信技术对造血的潜在益处的可能性。需要在更大的患者队列中进行进一步的长期研究，以阐明铁螯合治疗后造血恢复的效果。版权所有（C）2012 S. Karger AG，巴塞尔
Iron overload due to regular transfusions of packed red cells can cause multiple organ damage. Iron chelation therapy (ICT) is important in patients with aplastic anemia (AA) who require blood transfusions as supportive management. With the introduction of the oral iron chelator deferasirox, ICT has become more widely available and feasible. We studied 4 adult AA patients who had transfusion-induced iron overload and showed hematological improvement after ICT with oral deferasirox. Following deferasirox treatment, hemoglobin increased and serum ferritin levels decreased, and the patients subsequently became transfusion independent. Our experience raises the possibility of the potential benefit of ICT on hematopoiesis. Further long-term studies in larger patient cohorts are needed to clarify the effect of the restoration of hematopoiesis after iron chelation therapy. Copyright (C) 2012 S. Karger AG, Basel